Last reviewed · How we verify
NCT06757894
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Phase 2 trial testing Zuberitamab in Follicular Lymphoma (FL) in 50 participants. Not yet recruiting.
1 February 2028
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 February 2025 |
| Primary completion | 1 February 2028 |
| Estimated completion | 1 February 2034 |
| Sites | 1 location across China |
Drugs / interventions tested
- Zuberitamab — full drug profile →
- Bendamustine (BENDAMUSTINE) — full drug profile →
Conditions studied
- Follicular Lymphoma (FL) — all drugs for Follicular Lymphoma (FL) →
Sponsor
Sun Yat-sen University
Who can join
18 and older, any sex, with Follicular Lymphoma (FL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06757894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zuberitamab
Trials testing the same drug.
- NCT07261215 — Zuberitamab for EBV Infection Post-Allo-HSCT · Phase 2 · not yet recruiting
- NCT07480863 — Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL · Phase 2 · active not recruiting
- NCT07257510 — Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma · NA · recruiting
Other recruiting trials for Follicular Lymphoma (FL)
Currently open trials in the same condition.
- NCT06526793 — Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL · Phase 2 · recruiting
- NCT06091254 — A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Di · Phase 3 · recruiting
- NCT06097364 — A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to · Phase 3 · active not recruiting
- NCT05888493 — A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphom · Phase 3 · active not recruiting
- NCT03869619 — REal World Data in LYmphoma and Survival in Adults · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06757894 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 3 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06757894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing